Tranquis Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Tranquis Therapeutics's estimated annual revenue is currently $1.7M per year.(i)
  • Tranquis Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Tranquis Therapeutics has 11 Employees.(i)
  • Tranquis Therapeutics grew their employee count by -15% last year.

Tranquis Therapeutics's People

NameTitleEmail/Phone
1
Sr. VP Technical OperationsReveal Email/Phone
2
SVP, Clinical Evidence GenerationReveal Email/Phone
3
VP Medicinal Chemistry & Drug DiscoveryReveal Email/Phone
4
SVP Translational SciencesReveal Email/Phone
5
Chief Medical OfficerReveal Email/Phone
6
Sr. Manager, OperationsReveal Email/Phone
7
President & CEOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Tranquis Therapeutics?

Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide. Founded on ground-breaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis' novel therapeutic approach targets underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. The company's portfolio is comprised of small molecules which cross the blood-brain barrier, and the lead therapeutic candidate has demonstrated highly encouraging effects in challenging preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson's Disease (PD), and age-related cognitive impairment. Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer's Disease. For more information, visit www.tranquis.com.

keywords:N/A

N/A

Total Funding

11

Number of Employees

$1.7M

Revenue (est)

-15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Tranquis Therapeutics News

2022-03-22 - Tranquis Therapeutics Announces Participation in March Investor ...

Tranquis Therapeutics is a breakthrough biopharmaceutical company focused ... MD, at Stanford University, Tranquis' novel therapies work by...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.5M11-21%$18.6M
#2
$3.5M11-21%N/A
#3
$1.7M110%N/A
#4
$1M110%N/A
#5
$1M1110%N/A